APO Research
Talk to an analyst

APO RESEARCH · REPORT

OTC Anti-Infective Products

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global OTC Anti-Infective Products Market Outlook and Growth Opportunities 2026

29 December 2025196 pages

Choose your research edition.

Industry ResearchOTC Anti-Infective Products Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal OTC Anti-Infective Products Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal OTC Anti-Infective Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal OTC Anti-Infective Products Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal OTC Anti-Infective Products Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global OTC Anti-Infective Products market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for OTC Anti-Infective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for OTC Anti-Infective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for OTC Anti-Infective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the OTC Anti-Infective Products market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the OTC Anti-Infective Products market include Teva, Johnson & Johnson, NOVARTIS, MYLAN, Roche, Lingrui, Pfizer, CR SANJIU and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global OTC Anti-Infective Products market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of OTC Anti-Infective Products and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents OTC Anti-Infective Products sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the OTC Anti-Infective Products market size, projected growth trends, production technologies, key applications, and end-use industries.

OTC Anti-Infective Products Segment by Company

Teva

Johnson & Johnson

NOVARTIS

MYLAN

Roche

Lingrui

Pfizer

CR SANJIU

GSK

Bayer

Sun Pharma

Gilead Sciences

Cipla

Bausch Health

Astellas Pharma

OTC Anti-Infective Products Segment by Type

Antiviral

Antibacterial

Antifungal

Antiseptics

Others

OTC Anti-Infective Products Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

OTC Anti-Infective Products Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global OTC Anti-Infective Products status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions OTC Anti-Infective Products market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify OTC Anti-Infective Products significant trends, drivers, influence factors in global and regions.

6. To analyze OTC Anti-Infective Products competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OTC Anti-Infective Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OTC Anti-Infective Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OTC Anti-Infective Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the OTC Anti-Infective Products market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global OTC Anti-Infective Products industry.

Chapter 3: Detailed analysis of OTC Anti-Infective Products manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of OTC Anti-Infective Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of OTC Anti-Infective Products in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. OTC Anti-Infective Products Industry Trends Table 2. OTC Anti-Infective Products Industry Drivers Table 3. OTC Anti-Infective Products Industry Opportunities and Challenges Table 4. OTC Anti-Infective Products Industry Restraints Table 5. Global OTC Anti-Infective Products Revenue by Company (US$ Million) & (2021-2026) Table 6. Global OTC Anti-Infective Products Revenue Share by Company (2021-2026) Table 7. Global OTC Anti-Infective Products Sales Volume by Company (M Units) & (2021-2026) Table 8. Global OTC Anti-Infective Products Sales Volume Share by Company (2021-2026) Table 9. Global OTC Anti-Infective Products Average Price (US$/Unit) of Company (2021-2026) Table 10. Global OTC Anti-Infective Products Company Ranking, (2024-2026) & (USD Million) Table 11. Global OTC Anti-Infective Products Key Company Manufacturing Base & Headquarters Table 12. Global OTC Anti-Infective Products Company, Product Type & Application Table 13. Global OTC Anti-Infective Products Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global OTC Anti-Infective Products by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Antiviral Table 18. Significant Companies of Antibacterial Table 19. Significant Companies of Antifungal Table 20. Significant Companies of Antiseptics Table 21. Significant Companies of Others Table 22. Global OTC Anti-Infective Products Sales Volume by Type 2021 VS 2025 VS 2032 (M Units) Table 23. Global OTC Anti-Infective Products Sales Volume by Type (2021-2026) & (M Units) Table 24. Global OTC Anti-Infective Products Sales Volume by Type (2027-2032) & (M Units) Table 25. Global OTC Anti-Infective Products Sales Volume Share by Type (2021-2026) Table 26. Global OTC Anti-Infective Products Sales Volume Share by Type (2027-2032) Table 27. Global OTC Anti-Infective Products Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global OTC Anti-Infective Products Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global OTC Anti-Infective Products Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global OTC Anti-Infective Products Sales Value Share by Type (2021-2026) Table 31. Global OTC Anti-Infective Products Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Retail Pharmacies Table 33. Significant Companies of Online Pharmacies Table 34. Significant Companies of Hospital Pharmacies Table 35. Global OTC Anti-Infective Products Sales Volume by Application 2021 VS 2025 VS 2032 (M Units) Table 36. Global OTC Anti-Infective Products Sales Volume by Application (2021-2026) & (M Units) Table 37. Global OTC Anti-Infective Products Sales Volume by Application (2027-2032) & (M Units) Table 38. Global OTC Anti-Infective Products Sales Volume Share by Application (2021-2026) Table 39. Global OTC Anti-Infective Products Sales Volume Share by Application (2027-2032) Table 40. Global OTC Anti-Infective Products Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global OTC Anti-Infective Products Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global OTC Anti-Infective Products Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global OTC Anti-Infective Products Sales Value Share by Application (2021-2026) Table 44. Global OTC Anti-Infective Products Sales Value Share by Application (2027-2032) Table 45. Global OTC Anti-Infective Products Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 46. Global OTC Anti-Infective Products Sales by Region (2021-2026) & (M Units) Table 47. Global OTC Anti-Infective Products Sales Market Share by Region (2021-2026) Table 48. Global OTC Anti-Infective Products Sales by Region (2027-2032) & (M Units) Table 49. Global OTC Anti-Infective Products Sales Market Share by Region (2027-2032) Table 50. Global OTC Anti-Infective Products Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global OTC Anti-Infective Products Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global OTC Anti-Infective Products Sales Value Share by Region (2021-2026) Table 53. Global OTC Anti-Infective Products Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global OTC Anti-Infective Products Sales Value Share by Region (2027-2032) Table 55. Global OTC Anti-Infective Products Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global OTC Anti-Infective Products Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global OTC Anti-Infective Products Sales by Country: 2021 VS 2025 VS 2032 (M Units) Table 58. Global OTC Anti-Infective Products Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global OTC Anti-Infective Products Sales by Country (2021-2026) & (M Units) Table 60. Global OTC Anti-Infective Products Sales Market Share by Country (2021-2026) Table 61. Global OTC Anti-Infective Products Sales by Country (2027-2032) & (M Units) Table 62. Global OTC Anti-Infective Products Sales Market Share by Country (2027-2032) Table 63. Global OTC Anti-Infective Products Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global OTC Anti-Infective Products Sales Value Market Share by Country (2021-2026) Table 65. Global OTC Anti-Infective Products Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global OTC Anti-Infective Products Sales Value Market Share by Country (2027-2032) Table 67. Teva Company Information Table 68. Teva Business Overview Table 69. Teva OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Teva OTC Anti-Infective Products Product Portfolio Table 71. Teva Recent Development Table 72. Johnson & Johnson Company Information Table 73. Johnson & Johnson Business Overview Table 74. Johnson & Johnson OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Johnson & Johnson OTC Anti-Infective Products Product Portfolio Table 76. Johnson & Johnson Recent Development Table 77. NOVARTIS Company Information Table 78. NOVARTIS Business Overview Table 79. NOVARTIS OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. NOVARTIS OTC Anti-Infective Products Product Portfolio Table 81. NOVARTIS Recent Development Table 82. MYLAN Company Information Table 83. MYLAN Business Overview Table 84. MYLAN OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. MYLAN OTC Anti-Infective Products Product Portfolio Table 86. MYLAN Recent Development Table 87. Roche Company Information Table 88. Roche Business Overview Table 89. Roche OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Roche OTC Anti-Infective Products Product Portfolio Table 91. Roche Recent Development Table 92. Lingrui Company Information Table 93. Lingrui Business Overview Table 94. Lingrui OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Lingrui OTC Anti-Infective Products Product Portfolio Table 96. Lingrui Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Pfizer OTC Anti-Infective Products Product Portfolio Table 101. Pfizer Recent Development Table 102. CR SANJIU Company Information Table 103. CR SANJIU Business Overview Table 104. CR SANJIU OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. CR SANJIU OTC Anti-Infective Products Product Portfolio Table 106. CR SANJIU Recent Development Table 107. GSK Company Information Table 108. GSK Business Overview Table 109. GSK OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. GSK OTC Anti-Infective Products Product Portfolio Table 111. GSK Recent Development Table 112. Bayer Company Information Table 113. Bayer Business Overview Table 114. Bayer OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Bayer OTC Anti-Infective Products Product Portfolio Table 116. Bayer Recent Development Table 117. Sun Pharma Company Information Table 118. Sun Pharma Business Overview Table 119. Sun Pharma OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Sun Pharma OTC Anti-Infective Products Product Portfolio Table 121. Sun Pharma Recent Development Table 122. Gilead Sciences Company Information Table 123. Gilead Sciences Business Overview Table 124. Gilead Sciences OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Gilead Sciences OTC Anti-Infective Products Product Portfolio Table 126. Gilead Sciences Recent Development Table 127. Cipla Company Information Table 128. Cipla Business Overview Table 129. Cipla OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Cipla OTC Anti-Infective Products Product Portfolio Table 131. Cipla Recent Development Table 132. Bausch Health Company Information Table 133. Bausch Health Business Overview Table 134. Bausch Health OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Bausch Health OTC Anti-Infective Products Product Portfolio Table 136. Bausch Health Recent Development Table 137. Astellas Pharma Company Information Table 138. Astellas Pharma Business Overview Table 139. Astellas Pharma OTC Anti-Infective Products Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Astellas Pharma OTC Anti-Infective Products Product Portfolio Table 141. Astellas Pharma Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. OTC Anti-Infective Products Distributors List Table 145. OTC Anti-Infective Products Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. OTC Anti-Infective Products Product Image Figure 2. Global OTC Anti-Infective Products Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OTC Anti-Infective Products Sales Value (2021-2032) & (US$ Million) Figure 4. Global OTC Anti-Infective Products Sales (2021-2032) & (M Units) Figure 5. Global OTC Anti-Infective Products Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global OTC Anti-Infective Products Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Antiviral Image Figure 10. Antibacterial Image Figure 11. Antifungal Image Figure 12. Antiseptics Image Figure 13. Others Image Figure 14. Global OTC Anti-Infective Products Sales Volume by Type (2021 VS 2025 VS 2032) & (M Units) Figure 15. Global OTC Anti-Infective Products Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global OTC Anti-Infective Products Sales Volume Share by Type (2021-2032) Figure 17. Global OTC Anti-Infective Products Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global OTC Anti-Infective Products Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global OTC Anti-Infective Products Sales Value Share by Type (2021-2032) Figure 20. Retail Pharmacies Image Figure 21. Online Pharmacies Image Figure 22. Hospital Pharmacies Image Figure 23. Global OTC Anti-Infective Products Sales Volume by Application (2021 VS 2025 VS 2032) & (M Units) Figure 24. Global OTC Anti-Infective Products Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global OTC Anti-Infective Products Sales Volume Share by Application (2021-2032) Figure 26. Global OTC Anti-Infective Products Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global OTC Anti-Infective Products Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global OTC Anti-Infective Products Sales Value Share by Application (2021-2032) Figure 29. Global OTC Anti-Infective Products Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 30. Global OTC Anti-Infective Products Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global OTC Anti-Infective Products Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global OTC Anti-Infective Products Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America OTC Anti-Infective Products Sales Value (2021-2032) & (US$ Million) Figure 34. North America OTC Anti-Infective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe OTC Anti-Infective Products Sales Value (2021-2032) & (US$ Million) Figure 36. Europe OTC Anti-Infective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific OTC Anti-Infective Products Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific OTC Anti-Infective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America OTC Anti-Infective Products Sales Value (2021-2032) & (US$ Million) Figure 40. South America OTC Anti-Infective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa OTC Anti-Infective Products Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa OTC Anti-Infective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt OTC Anti-Infective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. OTC Anti-Infective Products Value Chain Figure 128. Manufacturing Cost Structure Figure 129. OTC Anti-Infective Products Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Antiviral
  • Antibacterial
  • Antifungal
  • Antiseptics
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Teva
  • Johnson & Johnson
  • NOVARTIS
  • MYLAN
  • Roche
  • Lingrui
  • Pfizer
  • CR SANJIU
  • GSK
  • Bayer
  • Sun Pharma
  • Gilead Sciences
  • Cipla
  • Bausch Health
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global OTC Anti-Infective Products Sales Value (2021-2032)
  4. 1.2.2 Global OTC Anti-Infective Products Sales Volume (2021-2032)
  5. 1.2.3 Global OTC Anti-Infective Products Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 OTC Anti-Infective Products Market Dynamics
  1. 2.1 OTC Anti-Infective Products Industry Trends
  2. 2.2 OTC Anti-Infective Products Industry Drivers
  3. 2.3 OTC Anti-Infective Products Industry Opportunities and Challenges
  4. 2.4 OTC Anti-Infective Products Industry Restraints
3 OTC Anti-Infective Products Market by Company
  1. 3.1 Global OTC Anti-Infective Products Company Revenue Ranking in 2025
  2. 3.2 Global OTC Anti-Infective Products Revenue by Company (2021-2026)
  3. 3.3 Global OTC Anti-Infective Products Sales Volume by Company (2021-2026)
  4. 3.4 Global OTC Anti-Infective Products Average Price by Company (2021-2026)
  5. 3.5 Global OTC Anti-Infective Products Company Ranking (2024-2026)
  6. 3.6 Global OTC Anti-Infective Products Company Manufacturing Base and Headquarters
  7. 3.7 Global OTC Anti-Infective Products Company Product Type and Application
  8. 3.8 Global OTC Anti-Infective Products Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global OTC Anti-Infective Products Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 OTC Anti-Infective Products Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 OTC Anti-Infective Products Market by Type
  1. 4.1 OTC Anti-Infective Products Type Introduction
  2. 4.1.1 Antiviral
  3. 4.1.2 Antibacterial
  4. 4.1.3 Antifungal
  5. 4.1.4 Antiseptics
  6. 4.1.5 Others
  7. 4.2 Global OTC Anti-Infective Products Sales Volume by Type
  8. 4.2.1 Global OTC Anti-Infective Products Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global OTC Anti-Infective Products Sales Volume by Type (2021-2032)
  10. 4.2.3 Global OTC Anti-Infective Products Sales Volume Share by Type (2021-2032)
  11. 4.3 Global OTC Anti-Infective Products Sales Value by Type
  12. 4.3.1 Global OTC Anti-Infective Products Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global OTC Anti-Infective Products Sales Value by Type (2021-2032)
  14. 4.3.3 Global OTC Anti-Infective Products Sales Value Share by Type (2021-2032)
5 OTC Anti-Infective Products Market by Application
  1. 5.1 OTC Anti-Infective Products Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global OTC Anti-Infective Products Sales Volume by Application
  6. 5.2.1 Global OTC Anti-Infective Products Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global OTC Anti-Infective Products Sales Volume by Application (2021-2032)
  8. 5.2.3 Global OTC Anti-Infective Products Sales Volume Share by Application (2021-2032)
  9. 5.3 Global OTC Anti-Infective Products Sales Value by Application
  10. 5.3.1 Global OTC Anti-Infective Products Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global OTC Anti-Infective Products Sales Value by Application (2021-2032)
  12. 5.3.3 Global OTC Anti-Infective Products Sales Value Share by Application (2021-2032)
6 OTC Anti-Infective Products Regional Sales and Value Analysis
  1. 6.1 Global OTC Anti-Infective Products Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global OTC Anti-Infective Products Sales by Region (2021-2032)
  3. 6.2.1 Global OTC Anti-Infective Products Sales by Region: 2021-2026
  4. 6.2.2 Global OTC Anti-Infective Products Sales by Region (2027-2032)
  5. 6.3 Global OTC Anti-Infective Products Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global OTC Anti-Infective Products Sales Value by Region (2021-2032)
  7. 6.4.1 Global OTC Anti-Infective Products Sales Value by Region: 2021-2026
  8. 6.4.2 Global OTC Anti-Infective Products Sales Value by Region (2027-2032)
  9. 6.5 Global OTC Anti-Infective Products Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America OTC Anti-Infective Products Sales Value (2021-2032)
  12. 6.6.2 North America OTC Anti-Infective Products Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe OTC Anti-Infective Products Sales Value (2021-2032)
  15. 6.7.2 Europe OTC Anti-Infective Products Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific OTC Anti-Infective Products Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific OTC Anti-Infective Products Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America OTC Anti-Infective Products Sales Value (2021-2032)
  21. 6.9.2 South America OTC Anti-Infective Products Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa OTC Anti-Infective Products Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa OTC Anti-Infective Products Sales Value Share by Country, 2025 VS 2032
7 OTC Anti-Infective Products Country-level Sales and Value Analysis
  1. 7.1 Global OTC Anti-Infective Products Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global OTC Anti-Infective Products Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global OTC Anti-Infective Products Sales by Country (2021-2032)
  4. 7.3.1 Global OTC Anti-Infective Products Sales by Country (2021-2026)
  5. 7.3.2 Global OTC Anti-Infective Products Sales by Country (2027-2032)
  6. 7.4 Global OTC Anti-Infective Products Sales Value by Country (2021-2032)
  7. 7.4.1 Global OTC Anti-Infective Products Sales Value by Country (2021-2026)
  8. 7.4.2 Global OTC Anti-Infective Products Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt OTC Anti-Infective Products Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt OTC Anti-Infective Products Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt OTC Anti-Infective Products Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva OTC Anti-Infective Products Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson OTC Anti-Infective Products Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 NOVARTIS
  14. 8.3.1 NOVARTIS Company Information
  15. 8.3.2 NOVARTIS Business Overview
  16. 8.3.3 NOVARTIS OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 NOVARTIS OTC Anti-Infective Products Product Portfolio
  18. 8.3.5 NOVARTIS Recent Developments
  19. 8.4 MYLAN
  20. 8.4.1 MYLAN Company Information
  21. 8.4.2 MYLAN Business Overview
  22. 8.4.3 MYLAN OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MYLAN OTC Anti-Infective Products Product Portfolio
  24. 8.4.5 MYLAN Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche OTC Anti-Infective Products Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Lingrui
  32. 8.6.1 Lingrui Company Information
  33. 8.6.2 Lingrui Business Overview
  34. 8.6.3 Lingrui OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lingrui OTC Anti-Infective Products Product Portfolio
  36. 8.6.5 Lingrui Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer OTC Anti-Infective Products Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 CR SANJIU
  44. 8.8.1 CR SANJIU Company Information
  45. 8.8.2 CR SANJIU Business Overview
  46. 8.8.3 CR SANJIU OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CR SANJIU OTC Anti-Infective Products Product Portfolio
  48. 8.8.5 CR SANJIU Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GSK OTC Anti-Infective Products Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bayer OTC Anti-Infective Products Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Sun Pharma
  62. 8.11.1 Sun Pharma Company Information
  63. 8.11.2 Sun Pharma Business Overview
  64. 8.11.3 Sun Pharma OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sun Pharma OTC Anti-Infective Products Product Portfolio
  66. 8.11.5 Sun Pharma Recent Developments
  67. 8.12 Gilead Sciences
  68. 8.12.1 Gilead Sciences Company Information
  69. 8.12.2 Gilead Sciences Business Overview
  70. 8.12.3 Gilead Sciences OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Gilead Sciences OTC Anti-Infective Products Product Portfolio
  72. 8.12.5 Gilead Sciences Recent Developments
  73. 8.13 Cipla
  74. 8.13.1 Cipla Company Information
  75. 8.13.2 Cipla Business Overview
  76. 8.13.3 Cipla OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Cipla OTC Anti-Infective Products Product Portfolio
  78. 8.13.5 Cipla Recent Developments
  79. 8.14 Bausch Health
  80. 8.14.1 Bausch Health Company Information
  81. 8.14.2 Bausch Health Business Overview
  82. 8.14.3 Bausch Health OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bausch Health OTC Anti-Infective Products Product Portfolio
  84. 8.14.5 Bausch Health Recent Developments
  85. 8.15 Astellas Pharma
  86. 8.15.1 Astellas Pharma Company Information
  87. 8.15.2 Astellas Pharma Business Overview
  88. 8.15.3 Astellas Pharma OTC Anti-Infective Products Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Pharma OTC Anti-Infective Products Product Portfolio
  90. 8.15.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 OTC Anti-Infective Products Value Chain Analysis
  2. 9.1.1 OTC Anti-Infective Products Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 OTC Anti-Infective Products Sales Mode & Process
  6. 9.2 OTC Anti-Infective Products Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 OTC Anti-Infective Products Distributors
  9. 9.2.3 OTC Anti-Infective Products Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst